TOKYO — Chugai Pharmaceutical has high hopes for obesity treatments it is working on with global partners Eli Lilly and Roche, as Japan’s most profitable drugmaker focuses on its core strengths.
Chugai, which is 61% owned by Swiss drugmaker Roche, has two candidates for treating obesity. One is orforglipron, an oral medicine that would join existing weight-loss medications Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, both of which are administered by injection.
